This represented 440,749 individuals who met Kidney Disease Improving Global Outcomes (KDIGO) clinical CKD criteria, ...

Drugs for diabetic kidney disease treatment have greatly expanded, allowing research and consensus on their optimal use.

The Kidney Disease: Improving Global Outcomes (KDIGO) heat map, produced by an international group of nephrologists, is a matrix of eGFR and proteinuria levels and is widely used to assess a ...

Canadian clinical trial company Arch Biopartners has dosed the first patient in Canada in its Phase II clinical trial of ...

The definition, classification and prognosis of chronic kidney disease: a KDIGO controversies conference report. Kidney Int 2011; 80: 17–28 CrossRef MEDLINE 2. KDIGO: KDIGO 2012 Clinical ...

The following is a summary of “Efficacy of continuous glucose monitoring in people living with diabetes and end stage kidney ...

Arch Biopartners doses first patient in Canada for phase II trial of LSALT peptide to treat cardiac surgery associated acute kidney injury: Toronto Wednesday, November 13, 2024, 1 ...

Charting, Price Performance, News & Related Contracts.

KDIGO Supports HCV+ Kidneys Going To HCV– Recipients "This update is intended to assist clinicians in the care of patients with HCV infection and CKD, including patients receiving dialysis (CKD ...

Ardelyx is currently reviewing the District Court’s decision and will consider all options related to the lawsuit.

including the recently updated Kidney Diseases Improving Global Outcomes (KDIGO) guideline for the management of CKD, a newly published consensus statement on renal genetics by The National Kidney ...